Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharm
Failed Content Uniformity Specifications
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
Severity not yet assessed
We have not scored this recall against our rubric yet, so we are not showing a severity rating or our usual guidance. The agency’s own notice below is the authoritative source — read it first.
Plain-English summary
Failed Content Uniformity Specifications
The recalled product
- Product
- Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, Mfg: Taro Pharmaceuticals U.S.A., Inc., Prod# (NDC): 68788-7865-05
- Manufacturer
- Preferred Pharmaceuticals, Inc.
- Category
- Drug — Drugs
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (6)
- Lot #: F1925G
- Expiry: 4/30/2027
- Lot #: E0925T
- Lot # D3025M
- Lot #: D0825D
- Expiry: 4/30/2027.
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Preferred Pharmaceuticals, Inc.
See all →- HighGeri-Care artificial tears lubricant eye drops recalled over sterility assurance
FDA (Drugs) · 2026-04-15
- ModerateOndansetron blister packs recalled because tablets are falling out
FDA (Drugs) · 2025-12-24
- ModerateClindamycin Hydrochloride Capsules Recalled for cGMP Deviations
FDA (Drugs) · 2025-05-07
- HighIbuprofen Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2024-09-04
- HighDuloxetine Delayed-Release Capsules Recalled for Nitrosamine Impurity
FDA (Drugs) · 2024-05-29